Skip to main content
. 2016 Aug 1;20:232. doi: 10.1186/s13054-016-1420-4

Table 1.

Patient demographics

Camicinal
Placebo 50 mg 75 mg
N = 12 N = 15 N = 6
Age in years, mean (SD) 46 (17) 63 (17) 42 (14)
Sex, n (%)
 Female: 2 (17) 6 (40) 1 (16)
 Male: 10 (83) 9 (60) 5 (83)
BMI (kg/m2), mean (SD) 28.8 (5.8) 29.0(6.2) 28.7 (3.7)
Height (cm), mean (SD) 173 (8) 172 (10) 178 (9)
Weight (kg), mean (SD) 86 (17) 86 (20) 91 (17)
Baseline renal function
 Baseline creatinine (μmol/L), mean (SD) 73.1 (33) 89.3 (84) 56.0 (7.3)
Baseline hepatic function
 ALT (IU/L), mean (SD) 44.6 (30) 34.7 (22) 58.3 (39)
 AST (IU/L), mean (SD) 43.2 (23) 35.6 (19) 55.2 (39)
 Total bilirubin (μmol/L), mean (SD) 10.5 (15) 10.2 (13) 5.7 (3.7)
Admission category, n (%)
 Trauma 5 (42) 4 (27) 1 (17)
 Head injury 1 (8) 3 (20) 1 (17)
 Respiratory failure 1 (8) 3 (20) 0
 Sepsis 2 (17) 2 (13) 0
 Other 3 (25) 3 (20) 4 (67)
Illness severity and duration
 APACHE II, median (min, max) 17.5 (6, 37) 19 (5, 30) 14 (7, 29)
 Days in ICU prior to enrollment, median (min, max) 4 (1, 9) 4 (2, 19) 4.5 (1, 7)
 Days in ICU prior to study, median (min, max) 5 (2, 10) 5.5 (2, 9) 5 (2, 19)
 Days in hospital prior to study, median (min, max) 5 (2, 10) 7 (3, 26) 5.5 (3, 9)
Concomitant chronic illnesses, n
 Diabetes 3 0 0
Concomitant medications, n
 Catecholamines 2 6 1
 Opioids/opiates 12 14 4
 Muscle relaxant 3 3 0
EN prior to enrollment
 Time from starting EN to development of feed intolerance; hours median (min, max) 29 (3, 162) 55 (5, 396) 50 (8, 81)
 EN administered (EN delivered – discarded) in 24 hours prior to study eligibility; mL, median (min, max) 1130 (415, 1547) 950 (140, 1920) 904 (305, 1388)

SD standard deviation, BMI body mass index, ALT alanine transaminase, AST aspartate transaminase, APACHE II, Acute Physiologic Assessment and Chronic Health Evaluation II, ICU intensive care unit, EN enteral nutrition